Stephen M. Ansell, MD, PhD, on Progress of CAR T-Cell Therapy

Video

The Mayo Clinic expert highlights exciting advancements being made in chimeric antigen receptor T-cell therapy for blood cancer.

At the 2019 ASH Annual Meeting, Stephen M. Ansell, MD, PhD, from Mayo Clinic, discussed a plenary session presentation focused on chimeric antigen receptor (CAR) T-cell therapy, and the excitement surround new bio-specific agents that will be available for patients.

Transcription:
I think there's been a lot of really encouraging data from ASH 2019 for large cell lymphoma, particularly in the relapsed/refractory space. So, I think we're learning a lot more about CAR T cells. But I think the most interesting data was data that was in the plenary session, looking at a bio-specific antibody targeting CD 20, and CD 3. So, basically taking the tumor cell and T cells and bringing them into close proximity with a very encouraging promising response rate, a little early data, so we still need longer follow up. But I think what was interesting is in CAR T cell failures, where we really are challenged for options to treat those patients, they showed that in those patients, kind of repurposing the T cells and bringing them back into close contact with the tumor but using the bio-specific antibody actually resulted in high response rates. So, I think this is a very encouraging space to watch as new agents become available, but particularly the bio-specific therapies, there are other bio-specifics that are similar, also with very good results. So, I think as a class this is a very promising approach.

Related Videos
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.